Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1974 1
1976 1
1979 1
1980 1
1981 4
1982 1
1984 2
1985 1
1986 2
1987 6
1988 10
1989 9
1990 8
1991 10
1992 13
1993 8
1994 14
1995 10
1996 7
1997 3
1999 1
2000 3
2001 3
2002 2
2003 1
2004 1
2006 1
2008 1
2012 1
2016 1
2017 2
2018 1
2020 2
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. Among authors: junien jl. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J. Boyer-Diaz Z, et al. Among authors: junien jl. J Hepatol. 2021 May;74(5):1188-1199. doi: 10.1016/j.jhep.2020.11.045. Epub 2020 Dec 2. J Hepatol. 2021. PMID: 33278455 Free article.
CCK antagonists: pharmacology and therapeutic interest.
Wettstein JG, Buéno L, Junien JL. Wettstein JG, et al. Among authors: junien jl. Pharmacol Ther. 1994;62(3):267-82. doi: 10.1016/0163-7258(94)90047-7. Pharmacol Ther. 1994. PMID: 7972336 Review.
Central nervous system pharmacology of neuropeptide Y.
Wettstein JG, Earley B, Junien JL. Wettstein JG, et al. Among authors: junien jl. Pharmacol Ther. 1995 Mar;65(3):397-414. doi: 10.1016/0163-7258(95)98598-k. Pharmacol Ther. 1995. PMID: 7644568 Review.
The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.
Derrett-Smith E, Clark KEN, Shiwen X, Abraham DJ, Hoyles RK, Lacombe O, Broqua P, Junien JL, Konstantinova I, Ong VH, Denton CP. Derrett-Smith E, et al. Among authors: junien jl. Arthritis Res Ther. 2021 Sep 6;23(1):234. doi: 10.1186/s13075-021-02592-x. Arthritis Res Ther. 2021. PMID: 34488870 Free PMC article.
136 results